Health Care • Biotechnology: Pharmaceutical Preparations
$16.20 ▲ +0.43
(+2.73%)
MKT CAP: $12.96B • VOL: 4.42M
52W L $12 52W H $29
SMMT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$1.27B | -$226.0M | -$609.6M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$1.08B | -$221.3M | -$614.9M |
| EBITDA (Normalized) | -$1.27B | -$225.9M | -$609.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$322.9M | -$142.1M | -$76.8M |
| Capital Expenditures (CapEx) | $657.0K | $139.0K | $0 |
| Free Cash Flow (FCF) | -$323.6M | -$142.2M | -$76.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -11.2% |
| Cash & Short-Term Equivalents | $225.3M | $104.9M | $783.8M |
| Total Debt (Short + Long Term) | $41.5M | $21.1M | $1.67B |
| Total Stockholders' Equity | $658.9M | $388.7M | $3.42B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SMMT.